As per the research report, the Apheresis Market in Latin America was worth USD 0.24 billion in 2021. It is estimated to be growing at a CAGR of 6.9%, to reach USD 0.33 billion by 2026.
The key factors driving the growth of the Latin American apheresis market are increased demand for blood and blood components coupled with the growing rate of blood donations. In addition, the increasing prevalence of leukemia, acute disseminated encephalomyelitis, multiple sclerosis, autoimmune hemolytic anemia, and neonatal cardiac lupus are driving the market's growth during the forecast period. For example, based on results published in the journal Neurology, in 2017, the prevalence of multiple sclerosis was recorded at 365 cases per 100,000, or 915,000 adults. In 2019, the prevalence rate of multiple sclerosis in Brazil was observed at 13.6 per 100,000 inhabitants. At the same time, the prevalence of multiple sclerosis in Mexico was recorded 25 per 100,000 inhabitants.
The prevalence of diseases such as leukemia and autoimmune disorders is increasing in children; further efforts to develop new apheresis treatment methods explicitly designed for children will present potential market opportunities. Adopting therapeutic apheresis in the pediatric population has shown some very successful rates, although providing therapeutic apheresis to children is a technologically difficult task. This is due to fewer recorded results in children since most apheresis therapies are developed from studies and trials in adult patients. The global incidence of acute lymphocytic leukemia ranges from 2.1 to 3.6 cases per 100,000 population per year, while in Mexico, the incidence is over 6 / 100,000 population per year. The incidence of leukemia in Brazil has increased over time and is currently the ninth most common cancer in the region. With a higher proportion of men, it causes 41.8 to 57.6 cases per million inhabitants.
However, the high cost of apheresis devices and therapeutic apheresis procedures, and the installation of the devices are estimated to limit the market growth to some degree. Furthermore, reducing the rate of blood donation due to strict regulations for blood donation will challenge the market in the coming years. Additionally, other factors such as shortage of skilled professionals, lack of awareness, and the complications following apheresis procedure are projected to hamper the growth of the Latin American apheresis market.
This research report on the Latin America Apheresis Market has been segmented and sub-segmented into the following categories:
By Product:
By Procedure:
By Application:
By Technology:
By End User:
By Country:
In 2020, Brazil accounted for the majority of the Latin America apheresis market share. Much of this region can be attributed to the higher incidence of leukemia (both in adults and children), advanced diagnosis technologies, a large population, and the growing presence of technologically advanced products in the country. Leukemia is a common pediatric cancer in the region, with around 49 million children under 15 years of age. The incidence rate among children aged 0-14 in Brazil is 54 per million. The presence of skilled doctors and advancing medical facilities are anticipated to present several growth opportunities during the forecast period.
Argentina is expected to lead the Latin American market and become the fastest growing regional market with a CAGR of 5.3% during the forecast period. The increasing burden of various blood-related diseases such as kidney disease, metabolic disease, cancer, and neurological disorders, the improving health care infrastructure, and the high levels of patient awareness are the main factors favoring the market growth in this region. In 2018, health spending represented more than 9.7% of Argentina's gross domestic product, up from 10.50% the previous year. In 2018, Argentina expressed the second-highest health expenditure in GDP among countries in Latin America and the Caribbean.
KEY MARKET PLAYERS:
Companies playing a leading role in the Latin American apheresis market profiled in the report are Asahi Kasei Medical Co., Ltd., Haemonetics Corporation, Terumo BCT, Inc., Fresenius Medical Care, Kawasumi Laboratories Inc., Cerus Corporation, HemaCare Corporation, Kaneka Corporation, B. Braun Melsungen AG, and Nikkiso Co., Ltd., Therakos, Inc., and Medica S.p.A.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Apheresis devices
5.1.2.1 Plasma separators
5.1.2.2 Plasma component separators
5.1.2.3 Immunoadsorption Columns
5.1.2.4 Plasma Perfusion Columns
5.1.2.5 Hemoperfusion Columns
5.1.3 Apheresis disposables
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Procedure
5.2.1 Introduction
5.2.2 Donor Apheresis
5.2.3 Therapeutic Apheresis
5.2.4 Y-o-Y Growth Analysis, By Procedure
5.2.5 Market Attractiveness Analysis, By Procedure
5.2.6 Market Share Analysis, By Procedure
5.3 Application
5.3.1 Introduction
5.3.2 Renal Diseases
5.3.3 Neurology
5.3.4 Cancer
5.3.5 Hematology
5.3.6 Autoimmune Diseases
5.3.7 Cardiovascular Diseases
5.3.8 Y-o-Y Growth Analysis, By Application
5.3.9 Market Attractiveness Analysis, By Application
5.3.10 Market Share Analysis, By Application
5.4 Technology
5.4.1 Centrifugation
5.4.1.1 Intermittent Flow
5.4.1.2 Continuous Flow
5.4.2 Membrane Separation
5.4.3 Y-o-Y Growth Analysis, By Technology
5.4.4 Market Attractiveness Analysis, By Technology
5.4.5 Market Share Analysis, By Technology
5.5 End user
5.5.1 Introduction
5.5.2 Private Blood Collection Centres
5.5.3 Public Blood Collection Centres
5.5.4 Hospitals
5.4.5 Y-o-Y Growth Analysis, By End user
5.4.6 Market Attractiveness Analysis, By End user
5.4.7 Market Share Analysis, By End user
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Procedure
6.1.3.4 By Application
6.1.3.5 By Technology
6.1.3.6 By End user
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Procedure
6.1.4.4 By Application
6.1.4.5 By Technology
6.1.4.6 By End user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Procedure
6.1.5.4 By Application
6.1.5.5 By Itechnology
6.1.5.6 By End user
6.2 Brazil
6.3 Mexico
6.4 Rest of Latin America
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Asahi Kasei Medical Co., Ltd.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Haemonetics Corporation
8.3 Terumo BCT, Inc.
8.4 Fresenius Medical Care
8.5 Kawasumi Laboratories Inc.
8.6 Cerus Corporation
8.7 Hemacare Corporation
8.8 Kaneka Corporation
8.9 Braun Melsungen AG
8.10 Nikkiso Co., Ltd.
8.11 Therakos, Inc.,
8.12 Medica S.p.A.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
